Quarterly report · Q2
4483.TEDINET S100PLQM
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.1bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥6.3bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥21.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥9.6bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥5.0bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.1bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥909m | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥1.1bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥4.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥908m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥678m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥597m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥677m | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥1.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥598m | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥112.1bn | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥62.1bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥58.1bn | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥50.5bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥30.9bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥61.6bn | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥31.2bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.9bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥28.3bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥61.6bn | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥31.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥28.9bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥41.5bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥13.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥15.5bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥21.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥3.8bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥48.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥25.29 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥11.76 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥57.74 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥20.26 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥10.64 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥23.86 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥11.14 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥54.16 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.06 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥10 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 55.0% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 50.2% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.8% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 72
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥126m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-09-30 | −¥67m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥126m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-09-30 | −¥67m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥189m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-09-30 | −¥99m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥933m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥890m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥84m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥42m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥192m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥144m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.9bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥42m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥24m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥903m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2022-07-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2022-07-01 → 2022-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥924m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2022-07-01 → 2022-09-30 | ¥485m |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥12.2bn |
| —segment total | revenue | 2022-07-01 → 2022-09-30 | ¥6.4bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥12.1bn |
| —segment total | revenue external | 2022-07-01 → 2022-09-30 | ¥6.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥126m |
| —segment total | revenue intersegment | 2022-07-01 → 2022-09-30 | ¥67m |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| —segment total | segment profit | 2022-07-01 → 2022-09-30 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥88m |
| Reconciling Itemsreconciling | revenue | 2021-07-01 → 2021-09-30 | −¥53m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥88m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-07-01 → 2021-09-30 | −¥53m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥157m |
| Reconciling Itemsreconciling | segment profit | 2021-07-01 → 2021-09-30 | −¥82m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥877m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥847m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥56m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥29m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥163m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥113m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥31m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥23m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥877m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2021-07-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2021-07-01 → 2021-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥730m |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2021-07-01 → 2021-09-30 | ¥400m |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥9.6bn |
| —segment total | revenue | 2021-07-01 → 2021-09-30 | ¥5.1bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥9.6bn |
| —segment total | revenue external | 2021-07-01 → 2021-09-30 | ¥5.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥88m |
| —segment total | revenue intersegment | 2021-07-01 → 2021-09-30 | ¥53m |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥2.6bn |
| —segment total | segment profit | 2021-07-01 → 2021-09-30 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 883
| Item | Context | Value | Unit |
|---|---|---|---|
| Inventories ca IFRS | Prior1YearInstant | 248000000 | JPY |
| Inventories ca IFRS | CurrentQuarterInstant | 291000000 | JPY |
| Other current assets ca IFRS | Prior1YearInstant | 693000000 | JPY |
| Other current assets ca IFRS | CurrentQuarterInstant | 650000000 | JPY |
| Current assets IFRS | Prior1YearInstant | 25979000000 | JPY |
| Current assets IFRS | CurrentQuarterInstant | 54590000000 | JPY |
| Property plant and equipment IFRS | Prior1YearInstant | 8420000000 | JPY |
| Property plant and equipment IFRS | CurrentQuarterInstant | 9447000000 | JPY |
| Goodwill IFRS | Prior1YearInstant | 19169000000 | JPY |
| Goodwill IFRS | CurrentQuarterInstant | 38878000000 | JPY |
| Intangible assets IFRS | Prior1YearInstant | 5527000000 | JPY |
| Intangible assets IFRS | CurrentQuarterInstant | 5779000000 | JPY |
| Other financial assets nca IFRS | Prior1YearInstant | 1298000000 | JPY |
| Other financial assets nca IFRS | CurrentQuarterInstant | 1654000000 | JPY |
| Deferred tax assets IFRS | Prior1YearInstant | 1516000000 | JPY |
| Deferred tax assets IFRS | CurrentQuarterInstant | 1577000000 | JPY |
| Other non current assets nca IFRS | Prior1YearInstant | 141000000 | JPY |
| Other non current assets nca IFRS | CurrentQuarterInstant | 164000000 | JPY |
| Non current assets IFRS | Prior1YearInstant | 36073000000 | JPY |
| Non current assets IFRS | CurrentQuarterInstant | 57502000000 | JPY |
| Assets IFRS | Prior1YearInstant | 62053000000 | JPY |
| Assets IFRS | CurrentQuarterInstant | 112092000000 | JPY |
| Borrowings cl IFRS | Prior1YearInstant | 777000000 | JPY |
| Borrowings cl IFRS | CurrentQuarterInstant | 20274000000 | JPY |
| Trade and other payables cl IFRS | Prior1YearInstant | 6182000000 | JPY |
| Trade and other payables cl IFRS | CurrentQuarterInstant | 5174000000 | JPY |
| Lease liabilities cl IFRS | Prior1YearInstant | 689000000 | JPY |
| Lease liabilities cl IFRS | CurrentQuarterInstant | 780000000 | JPY |
| Income taxes payable cl IFRS | Prior1YearInstant | 999000000 | JPY |
| Income taxes payable cl IFRS | CurrentQuarterInstant | 745000000 | JPY |
| Contract liabilities cl IFRS | Prior1YearInstant | 1843000000 | JPY |
| Contract liabilities cl IFRS | CurrentQuarterInstant | 2121000000 | JPY |
| Other current liabilities cl IFRS | Prior1YearInstant | 1140000000 | JPY |
| Other current liabilities cl IFRS | CurrentQuarterInstant | 998000000 | JPY |
| Total current liabilities IFRS | Prior1YearInstant | 11633000000 | JPY |
| Total current liabilities IFRS | CurrentQuarterInstant | 30095000000 | JPY |
| Borrowings ncl IFRS | Prior1YearInstant | 10928000000 | JPY |
| Borrowings ncl IFRS | CurrentQuarterInstant | 11826000000 | JPY |
| Lease liabilities ncl IFRS | Prior1YearInstant | 5401000000 | JPY |
| Lease liabilities ncl IFRS | CurrentQuarterInstant | 5534000000 | JPY |
| Retirement benefit liability ncl IFRS | Prior1YearInstant | 319000000 | JPY |
| Retirement benefit liability ncl IFRS | CurrentQuarterInstant | 338000000 | JPY |
| Provisions ncl IFRS | Prior1YearInstant | 276000000 | JPY |
| Provisions ncl IFRS | CurrentQuarterInstant | 451000000 | JPY |
| Deferred tax liabilities IFRS | Prior1YearInstant | 769000000 | JPY |
| Deferred tax liabilities IFRS | CurrentQuarterInstant | 755000000 | JPY |
| Contract liabilities ncl IFRS | Prior1YearInstant | 1560000000 | JPY |
| Contract liabilities ncl IFRS | CurrentQuarterInstant | 1481000000 | JPY |
| Non current labilities IFRS | Prior1YearInstant | 19254000000 | JPY |
| Non current labilities IFRS | CurrentQuarterInstant | 20387000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |